Teleflex Incorporated (TFX) has acquired Semprus BioSciences, a biomedical company and spin out from Massachusetts Institute of Technology or MIT. This purchase includes the core Semprus Sustain Technology. Teleflex said the transaction brings to it an innovative and patented platform technology that serves as the basis for next-generation medical devices. The technology is designed to provide the benefits of reducing complications such as thrombosis and microbial adhesion over long durations.
Sustain is a long-lasting, covalently bonded, non-leaching polymer that is designed to reduce the attachment of platelets and blood proteins at the device surface. The initial focus for the technology is its use in vascular device applications, and a Semprus Sustain coated Peripherally Inserted Central Catheter is currently pending 510(k) clearance from the Food and Drug Administration. Sustain is also pending CE Mark approval in Europe.
According to the deal, Teleflex has acquired Semprus BioSciences for an upfront payment of $30 million. Teleflex may be required to make certain additional payments based upon the achievement of certain regulatory and revenue milestones over the next several years.
For comments and feedback: editorial@rttnews.com